Trials / Completed
CompletedNCT02935634
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the preliminary efficacy, safety, and tolerability of Nivolumab in combination with Ipilimumab or other treatment therapies in participants with advanced gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| BIOLOGICAL | Ipilimumab | Specified dose on specified days |
| BIOLOGICAL | Relatlimab | Specified dose on specified days |
| BIOLOGICAL | BMS-986205 | Specified dose on specified days |
| DRUG | Rucaparib | Specified dose on specified days |
Timeline
- Start date
- 2016-11-29
- Primary completion
- 2022-05-11
- Completion
- 2022-05-11
- First posted
- 2016-10-17
- Last updated
- 2023-06-09
- Results posted
- 2023-06-09
Locations
35 sites across 9 countries: United States, Australia, Canada, Germany, Israel, Italy, Netherlands, Singapore, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02935634. Inclusion in this directory is not an endorsement.